We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Societal CDMO Inc

Societal CDMO Inc (SCTL)

Closed July 13 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.00 Day's Range 0.00
0.26 52 Week Range 1.10
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About Societal CDMO Inc

Recro Pharma, Inc. is registered with the U.S. Security and Exchange Commission . Recro Pharma, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all ... Recro Pharma, Inc. is registered with the U.S. Security and Exchange Commission . Recro Pharma, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Recro Pharma, Inc.. Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Show more

Pharmaceutical Preparations
Pharmaceutical Preparations
Exton, Pennsylvania, USA
Societal CDMO Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SCTL. The last closing price for Societal CDMO was $1.10. Over the last year, Societal CDMO shares have traded in a share price range of $ 0.26 to $ 1.10.

Societal CDMO currently has 105,690,922 shares outstanding. The market capitalization of Societal CDMO is $116.26 million. Societal CDMO has a price to earnings ratio (PE ratio) of -16.64.

SCTL Latest News

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a...

CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.

CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract development and manufacturing organization...

Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP


View all
  • Most Active
  • % Gainers
  • % Losers
VEVVicinity Motor Corporation
$ 0.7131
QLGNQualigen Therapeutics Inc
$ 0.428851
IVPInspire Veterinary Partners Inc
$ 10.52
TOYOTOYO Company Ltd
$ 2.699
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
SISIShineco Inc
$ 0.8446
MCACMonterey Capital Acquisition Corporation
$ 3.54
MCACUMonterey Capital Acquisition Corporation
$ 7.64
GENEGenetic Technologies Ltd
$ 0.80
KZIAKazia Therapeutics Ltd
$ 0.8975
QLGNQualigen Therapeutics Inc
$ 0.428851
MAXNMaxeon Solar Technologies Ltd
$ 0.237
NVDANVIDIA Corporation
$ 129.24
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
LCIDLucid Group Inc
$ 4.25

SCTL Discussion

View Posts
cashforme cashforme 4 months ago
Here we go!
cashforme cashforme 4 months ago
Sctl looks to be on the run today!
Monksdream Monksdream 11 months ago
SCTL new 52 week low
cashforme cashforme 1 year ago
I think there is a lot of upside here!
cashforme cashforme 1 year ago
Looking good!
cashforme cashforme 1 year ago
Starting to look good here!
makinezmoney makinezmoney 2 years ago
$SCTL: LETTTTTttttssssssssssss GOOOOOooooooooooooooo

Ready to TRADE this

Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
March 21, 2022 07:00 ET | Source: Recro Pharma, Inc.

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of Delivering Impactful Medicines to Society

New Ticker (NASDAQ: SCTL) to Initiate Trading on March 22, 2022

SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result of its acquisition and successful integration of IriSys, Inc. into the organization.

Since the August 2021 acquisition of IriSys, Societal CDMO has worked to strategically and thoughtfully integrate that business into its legacy operations to establish a stronger and more versatile CDMO capable of attracting and efficiently servicing a broader range of customers domestically and abroad. The result of these efforts has been the successful expansion of Societal CDMO’s physical footprint to include facilities on both coasts of the U.S., significant diversification of its customer base, expansion of its suite of service offerings, and enhancement of its industry expertise through augmentation of its leadership and employee base. The new identity is intended to capture the company’s vision for establishing itself as a premier, trusted growth-focused CDMO that is expertly and actively facilitating its customers’ objectives of delivering impactful medicines to society.

“When we set out to rebrand Recro, we sought a name and identity that carried with it a purpose, one which exemplified the commitment our employees demonstrate every day to making a positive impact within communities across the country and around the world. At the same time, we were also focused on effectively communicating our evolution as a partner to our clients, as well as our people, both today and in the future. We believe the name Societal CDMO, along with our new tagline of ‘Bringing Science to Society,’ captures not only where we find ourselves as a company today, but it reflects our inspiration for future growth as an organization,” said David Enloe, chief executive officer of Societal CDMO.

Societal CDMO is in the process of developing a new corporate website. While the full site is not yet live, a preview of the new website can now be seen at Once the new website is live, it will be available

Effective at market open on Tuesday, March 22, 2022, trading for Societal CDMO will begin under the symbol “SCTL” (NASDAQ: SCTL). The company’s common stock will continue to trade under the ticker symbol “REPH” until market close today, March 21, 2022. The corporate name change to Societal CDMO does not affect the rights of the company’s stockholders and no action is required by stockholders with respect to the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

About Societal CDMO
Societal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and manufacturing organization (CDMO) with capabilities spanning pre-Investigational New Drug (IND) development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms with a primary focus in the area of small molecules. With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified-release dosage forms, Societal CDMO has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 145,000 square feet, in Gainesville, Georgia and San Diego, California.

Societal CDMO: Bringing Science to Society. For more information about Societal CDMO’s customer solutions, visit

Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipate”, “believe”, “could”, “estimate”, “upcoming”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will” and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause the company’s actual outcomes to differ materially from those expressed in or underlying these forward-looking statements include risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the customer ordering patterns or inventory rebalancing or disruption in raw materials or supply chain; demand for the company’s services, which depends in part on customers’ research and development and the clinical plans and market success of their products; customers’ changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with the company’s manufacturing services; the average profitability, or mix, of the products the company manufactures; the company’s ability to enhance existing or introduce new services in a timely manner; fluctuations in the costs, availability, and suitability of the components of the products the company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or the company’s customers facing increasing or new competition. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results presented herein along with those risks and uncertainties discussed in our filings with the Securities and Exchange Commission at These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

Tags$SCTL $reph Recro Societal CDMO CDMO contract manufacturing pharmacueitcal drug
Contact Data
Stephanie Diaz (Investors)
Vida Strategic Partners

Tim Brons (Media)
Vida Strategic Partners

Ryan D. Lake (CFO)
Societal CDMO

Your Recent History

Delayed Upgrade Clock